Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs

Bristol Myers Squibb has struck a deal to buy Forbius for its portfolio of TGF-beta inhibitors. The takeover will give Bristol Myers control of a clinical-phase inhibitor of TGF-beta 1 and 3 that Forbius is developing to increase the activity of immune checkpoint inhibitors.